The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for sepsis diagnostic research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness.
The global spread of covid-19 and the emerging cases of sepsis among covid-19 patients are likely to increase the demand for rapid diagnosis, accelerating the utilization of instruments, reagents, & assay kits for detection of sepsis. Lockdowns resulting from the pandemic caused people to delay undergoing health checkups, affecting the number of tests performed and reagent sales.
The current COVID-19 pandemic has highlighted the risk faced by older adults, who are more susceptible to complications, including acute respiratory distress syndrome, usually due to pneumonia, which increases the risk of developing sepsis. Thus, increasing the need for early diagnosis of sepsis among patients with covid-19 infections.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155
The most common hospital-acquired infections (HAIs) are urinary tract infections, pneumonia, and sepsis. HAIs can lead to sepsis in immunocompromised patients, geriatric patients, and patients suffering from chronic illnesses.
The cost of molecular diagnostic tests is between USD 300 and USD 3,000, which is very high compared to the cost of blood culture tests, priced as low as ~USD 28–35. Companies focus on developing automated diagnostic devices based on advanced technologies, such as molecular diagnostics, on detecting sepsis but due to limited budgets, government hospitals (especially in emerging nations) and academic research laboratories cannot afford such systems.
Sepsis is a very difficult condition to diagnose and the risk of mortality increases by 7.6% with a delay of even 1 minute in antibiotic administration in septic shock patients with hypertension. Thus, increasing the need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis.
Key Market Players
The prominent players operating in the global sepsis diagnostics market include bioMérieux (France), Becton, Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), Luminex (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), Immunexpress (Australia), Axis-Shield Diagnostics (UK), Quidel Corporation (US), Siemens Healthineers (Germany), EKF Diagnostics (UK), Seegene Inc., (South Korea), Boditech Med (South Korea), Alifax S.r.l. (Italy), AdvanDx (US), (US), Immunexpress (Australia), and Axis-Shield Diagnostics (UK).